Navigation Links
Genzyme Announces Presentation of New Positive Data on Carticel(R)
Date:3/10/2008

d not undergone a marrow stimulation technique prior to treatment with ACI.

"The data show that in this patient population marrow stimulation techniques like microfracture are not benign and can compromise a patient's ability to benefit from a subsequent treatment with ACI, effectively limiting their future treatment options," said Tom Minas, MD, an internationally renowned orthopaedic surgeon for his extensive work in the field of Cartilage Repair and principal investigator in this study. "Orthopaedic surgeons should reconsider using marrow stimulation techniques as first-line treatment for patients with larger chondral lesions. These techniques should be reserved for patients with smaller defects, in younger patients, where a good result is more predictable."

A Unique Cell Therapy

More than 14,000 patients in the United States have had Carticel implants. Carticel is used by orthopaedic surgeons to treat patients who have clinically significant articular cartilage lesions on the thigh bone part of the knee caused by acute or repetitive trauma that have not responded to a prior cartilage repair procedure. Carticel should only be used in conjunction with debridement, placement of a periosteal flap and rehabilitation. The independent contributions of the autologous cultured chondrocytes and other components of the therapy to outcome are unknown. Carticel employs a unique process to grow a patient's own cartilage cells for implantation to correct certain types of damage. The treatment starts when an orthopaedic surgeon trained in the use of Carticel provides Genzyme with a biopsy of healthy cartilage taken from a patient's knee in an arthroscopic procedure. Technicians at Genzyme's cell culture laboratory in Cambridge, MA, use proprietary methods to grow millions of cells from this biopsy. The cells are then delivered to the hospital, where the surgeon implants them into the patient's knee defect in a surgical procedure.

Carticel was the fir
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
2. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
3. Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML
4. Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... BOTHELL, Wash. , Sept. 23, 2014   ... a leading developer, manufacturer and marketer of proprietary clinical ... media and precision thermal shipping products ... announced two new additions to its Scientific Advisory Board.  ... and Anthony Davies , PhD. Dr. ...
(Date:9/22/2014)... BARCELONA, Spain , September 23, 2014 ... sponsors to meet health authorities, increasing rigor for trial ... The life sciences industry,s largest TMF survey to date ... sponsors that plan to provide auditors with remote access ... 32% of TMF owners surveyed in the ...
(Date:9/22/2014)... NEW YORK , Sept. 22, 2014 /PRNewswire/ ... is in mature stage. It is largely a ... endoscopy suite expansion. The mergers, acquisitions and partnerships ... Europe . This research service provides details ... competitive environment and pricing trends across the country. ...
Breaking Medicine Technology:BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 3BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 4BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 6BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 7Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 2Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 3Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 4Automated Endoscope Reprocessor Market Trends in Western Europe 2Automated Endoscope Reprocessor Market Trends in Western Europe 3
... RoundTable Healthcare Partners ("RoundTable"), an operating-oriented private equity ... today that it has entered into a definitive ... Clinical Innovations, LLC ("Clinical"), to The Pritzker Group, ...  Terms of the transaction were not disclosed. ...
... Amira Pharmaceuticals, Inc. announced today that it has ... lysophosphatidic acid (LPA)-related program, autotaxin.  Autotaxin is an enzyme ... a number of diseases including rheumatoid arthritis, glioblastoma, lung, ... pleased to announce that we have identified an orally ...
Cached Medicine Technology:RoundTable Healthcare Partners Announces Sale of Clinical Innovations, LLC to The Pritzker Group 2Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor 2
(Date:9/23/2014)... Toronto (PRWEB) September 23, 2014 ... the Canadian specialty market, is now providing U.S. ... its new 160,000-square-foot distribution center coupled with its ... Canadian healthcare industry has historically been difficult for ... to government regulation complexities. As a result of ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 The print ... of the Metro, with a circulation of approximately 327,720 ... component is distributed nationally through a vast social media ... and partner outlets. To explore the digital version of ... features an exclusive interview with Michael Landsberg, host of ...
(Date:9/23/2014)... 2014 Antibiotics revolutionized health care in the ... killed thousands of people. But bacteria are also ... bacteria are popping up more frequently. This week,s ... of new antibiotics and discusses the prospects for ... Why should you finish your pills if you ...
(Date:9/23/2014)... to what is often assumed about single parents, particularly ... The Kinsey Institute has found that single parents of ... as often as singles without children -- and more ... study, "Dating and Sexual Behavior Among Single Parents of ... in the Journal of Sex Research prior ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 On September 23, ... Keith Simmons for an episode. Simmons is the founder of ... believed the audience would like to know. At the start ... the idea to start this magazine?” Simmons replied by saying, ... sales person. In 2005, I quit that and decided to ...
Breaking Medicine News(10 mins):Health News:AmerisourceBergen Paves Path to Canadian Markets 2Health News:AmerisourceBergen Paves Path to Canadian Markets 3Health News:‘Sick, not weak’: Mediaplanet’s "Mental Health” Campaign Dispels Stigmas and Bolsters Support for the One in Five Canadians Suffering Mental Illness 2Health News:Kinsey study of single parents' dating, sexual activity contradicts assumptions 2Health News:My Positive Perspective Airs Episode With the Founder of Traveler of Charleston Magazine 2
... Society for Gastrointestinal Endoscopy (ASGE) and the American Society ... new white paper on the potential role of endoscopic ... like Type 2 diabetes. The white paper ... in both GIE: Gastrointestinal Endoscopy, the peer-reviewed ...
... standards for teaching women and clinicians how to perform ... to detect lumps earlier and save lives. Widely-publicized ... of cancer. The Center for Disease Control reports that ... most common cancer among American females. The National ...
... keep blood vessels open to treat heart disease are ... the Journal of Interventional Cardiology . A case ... of the Detroit Medical Center Cardiovascular Institute, and her ... after the recently marketed Ion stent (Boston Scientific, Natick, ...
... of organic horticultural crops frequently fall below those of ... of organic production. Researchers recently studied the growth and ... with vermicompost and compared the results with plants grown ... area is needed to provide a base of information ...
... has found that people are willing to pay up to 29.91 ... Researchers surveyed the public in the two major urban centres ... were willing to pay in council tax or rent/mortgage payments for ... willing to pay more for greener spaces with greater tree coverage. ...
... poisonous snakes, a group of researchers at the University of ... small black, yellow and red serpent called the Texas coral ... insights into chronic and acute pain and provides new ... combat pain. The venom contains a toxic mixture of ...
Cached Medicine News:Health News:ASMBS and ASGE issue white paper on endoscopic bariatric therapies (EBTs) 2Health News:ASMBS and ASGE issue white paper on endoscopic bariatric therapies (EBTs) 3Health News:Public willing to pay more for greener urban spaces 2Health News:Public willing to pay more for greener urban spaces 3Health News:Snake spills venomous secrets 2Health News:Snake spills venomous secrets 3
... is a leading provider of immunofluorescence assays, ... menu that includes kits for autoimmune diseases, ... miscellaneous conjugates and components. Our Impact IFA ... of substrates and kit sizes to choose ...
... a leading provider of immunofluorescence assays, with ... that includes kits for autoimmune diseases, infectious ... conjugates and components. Our Impact IFA Test ... substrates and kit sizes to choose from. ...
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
Medicine Products: